Immuron Ltd
IMC
Company Profile
Business description
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Contact
Chapman Street
Unit 10, 25-37
Blackburn North
MelbourneVIC3130
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,374.00 | 82.20 | -0.97% |
| CAC 40 | 7,722.91 | 47.57 | -0.61% |
| DAX 40 | 23,251.62 | 164.97 | 0.71% |
| Dow JONES (US) | 41,317.43 | 564.47 | 1.39% |
| FTSE 100 | 8,596.35 | 99.55 | 1.17% |
| HKSE | 22,504.68 | 385.27 | 1.74% |
| NASDAQ | 17,977.73 | 266.99 | 1.51% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,421.25 | 93.36 | 0.76% |
| S&P 500 | 5,686.67 | 82.53 | 1.47% |
| S&P/ASX 200 | 8,157.80 | 80.20 | -0.97% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |